Glycogen Storage Disease D006008

Description

A group of inherited metabolic disorders involving the enzymes responsible for the synthesis and degradation of glycogen. In some patients, prominent liver involvement is presented. In others, more generalized storage of glycogen occurs, sometimes with prominent cardiac involvement.   MeSH

Subtype Terms (9)

Glycogen Storage Disease Type I
7 drugs (3 approved, 4 experimental)

Glycogen Storage Disease Type II
28 drugs (15 approved, 13 experimental)

Glycogen Storage Disease Type IIb
1 experimental drug

Glycogen Storage Disease Type III
4 drugs (1 approved, 3 experimental)

Glycogen Storage Disease Type IV
2 drugs (1 approved, 1 experimental)

Glycogen Storage Disease Type V
4 drugs (2 approved, 2 experimental)


Phase 4 Indicated Drugs (1)

Phase 2 Indicated Drugs (2)

Phase 1 Indicated Drugs (1)

Other Experimental Indicated Drugs (2)


Organization Involved with Phase 4 Indications (2)

Organization Involved with Phase 1 Indications (1)

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.